ArticleJournal of translational autoimmunity2023
Antiphospholipid antibodies induce proinflammatory and procoagulant pathways in endothelial cells.
Article in Journal of translational autoimmunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Reference intervals for aCL and anti-β2GPI IgAGM antibodies in a large health-inspection population: a foundational study for combined-isotype assay interpretation.Lupus science & medicine · 2026Article
- Co-Occurrence of Psoriasis/Psoriatic Arthritis and Antiphospholipid Syndrome: A Series of Nine Patients from a Single Centre and Literature Review.Mediterranean journal of rheumatology · 2025Article
- A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry.Frontiers in immunology · 2025Article
- Association between antiphospholipid antibodies, rheumatic-immune inflammation, and coronary in-stent restenosis.Frontiers in cardiovascular medicine · 2025Article
- New advances in genomics and epigenetics in antiphospholipid syndrome.Rheumatology (Oxford, England) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is an autoimmune thrombophilia characterized by recurrent thrombotic events and/or pregnancy morbidity in the presence of antiphospholipid antibodies detected either as anti-cardiolipin, anti-β2 Glycoprotein I (anti-β2GPI) or Lupus anticoagulant (LA). Endothelial deregulation characterizes the syndrome. To address gene expression changes accompanying the development of autoimmune phenotype in endothelial cells in the context of APS, we performed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.